SLS Stock Analysis: Buy, Sell, or Hold?
SLS - SELLAS Life Sciences Group, Inc. Common Stock
$13.34
0.13 (0.98%)
â˛
5d:
-6.88%
30d:
+33.27%
90d:
+47.08%
WAIT
LOW Confidence
Analysis Updated: Aug 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 27, 2026 at $15.21 · last confirmed Aug 31, 2026
Strength: 6.8/10
Get Alerted When SLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SLS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SLS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SLS is currently trading at $13.34, which is considered slightly high relative to its 30-day fair value range of $10.84 to $13.82.
Technical Outlook: Technically, SLS is in a strong uptrend. Immediate support is located at $12.53, while resistance sits at $15.67.
Market Sentiment: SLS scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.50 (+143.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SLS is in a strong uptrend. Immediate support is located at $12.53, while resistance sits at $15.67.
Market Sentiment: SLS scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.50 (+143.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$10.84 -
$13.82
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
Protect Your Profits
Holding SLS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 143.6% below Wall St target ($32.50)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.84 -
$13.82
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$12.53
Resistance Level
$15.67
Current Trend
Strong Uptrend
Technical data as of
Aug 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-133.40
Wall Street Target
$32.50
(+143.6%)
Revenue Growth (YoY)
-82.5%
Share & Embed Analysis
Last updated: August 31, 2026 8:11 PM ET
Data refreshes hourly during market hours. Next update: 9:11 PM
Data refreshes hourly during market hours. Next update: 9:11 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 52 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 46 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 52 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 49 HOLD |
Advanced SLS Option Strategies
Professional options setups generated by AI based on today's SLS price and gamma walls.
